Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Policy / Pricing
  • What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge
  • Policy / Pricing

What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge

KFF Medicare

This brief describes current coverage of GLP-1s in Medicare and Medicaid, the Centers for Medicare Medicaid Services' (CMS) efforts to expand access and lower costs for GLP-1s through temporary demons

Metabolic & GLP-1

Read full story

pharminent May 11, 2026 (Last updated: May 15, 2026)

KFF Medicare

This brief describes current coverage of GLP-1s in Medicare and Medicaid, the Centers for Medicare Medicaid Services’ (CMS) efforts to expand access and lower costs for GLP-1s through temporary …

Metabolic & GLP-1

Read full story

Post navigation

Previous: FDA Advances Drug Repurposing to Address Unmet Medical Needs
Next: Third Circuit Affirms Denial of Stelara Biosimilar Injunction

Related Stories

  • Policy / Pricing

Mid-cap biotechs join Trump’s latest round of drug pricing deals

pharminent September 1, 2026
  • Policy / Pricing

MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones

pharminent August 27, 2026
  • Policy / Pricing

MFN affecting Swiss medicines access, says Interpharma

pharminent August 13, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.